Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia

Pediatr Infect Dis J. 2013 Sep;32(9):962-4. doi: 10.1097/INF.0b013e318298dfb8.

Abstract

The study through Monte Carlo simulation of β-lactam pharmacokinetic/pharmacodynamic target attainment and determination of subsequent serum concentrations of piperacillin-tazobactam administered through continuous infusion to children treated for fever and neutropenia shows that 400 mg/kg/day has the highest probability of target attainment against Pseudomonas aeurginosa in our oncology ward compared with the standard regimen of 300 mg/kg/day.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / administration & dosage*
  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacology
  • Child
  • Female
  • Fever of Unknown Origin / complications
  • Fever of Unknown Origin / drug therapy*
  • Humans
  • Infusions, Intravenous / methods
  • Male
  • Neutropenia / drug therapy*
  • Penicillanic Acid / administration & dosage
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / pharmacokinetics
  • Penicillanic Acid / pharmacology
  • Piperacillin / administration & dosage
  • Piperacillin / pharmacokinetics
  • Piperacillin / pharmacology
  • Piperacillin, Tazobactam Drug Combination
  • Pseudomonas Infections / drug therapy*
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Piperacillin, Tazobactam Drug Combination
  • Penicillanic Acid
  • Piperacillin